New blood test detects mesothelioma

A promising new blood test is highly accurate at detecting whether a person exposed to asbestos has early-stage pleural mesothelioma, research finds.

The biomarker, fibulin-3, outperforms current techniques and could lead to earlier detection of the cancer, which has been notoriously difficult due to its long latency period.

Patients diagnosed with mesothelioma live an average of 12 months, despite advances in chemotherapy, radiotherapy and surgery, US researchers wrote Thursday in the New England